https://www.thebodypro.com/category/fda-approved-hiv-medications

FDA-Approved HIV Medications

The Latest

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring

Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.

Significant Drug-Drug Interaction Between Dolutegravir and Isoniazid-Rifapentine Img
Tuberculosis

Significant Drug-Drug Interaction Between Dolutegravir and Isoniazid-Rifapentine

Dolutegravir (Tivicay) given with once-weekly isoniazid-rifapentine led to marked cytokine release and serious adverse events in a drug-drug interaction study.

Promo Image
Neurocognitive

This Week in HIV Research: This Is Your Brain on (HIV) Drugs

NeuroAIDS while on efavirenz vs. common NRTIs; HIV and the smoking cessation aid varenicline; PrEP adherence after positive partners start treatment; and Ugandans underreporting their antiretroviral use.

Promo Image
IDWeek

Late 2017 HIV Conferences Focus on Antiretrovirals and Comorbidities

2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...

Promo Image
IDWeek

A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017

Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.

Darunavir/Cobicistat/FTC/TAF: 24-Week Interim Results From Phase 3 Switch Study Img
IAS (International AIDS Society) Conference

Darunavir/Cobicistat/FTC/TAF: 24-Week Interim Results From Phase 3 Switch Study

Planned 24-week interim results from a 48-week phase 3 study were presented at IAS 2017 and showed that switching to this fixed-dose combination maintained undetectable viral load.

Promo Image
CROI (Conference on Retroviruses and Opportunistic Infections)

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

Newer Guidelines Widen Statin Treatment Gap in HIV and HCV-Positive Veterans Img
Hepatitis C

Newer Guidelines Widen Statin Treatment Gap in HIV and HCV-Positive Veterans

Mark Mascolini reports on a new study comparing statin indications in male veterans with HIV, HCV or both with three sets of cholesterol guidelines and examining why almost one-third of statin-eligible veterans were not getting the drugs.

Sofosbuvir + Velpatasvir (Epclusa) -- Interactions With Other Medicines Img
Hepatitis C

Sofosbuvir + Velpatasvir (Epclusa) -- Interactions With Other Medicines

The fixed-dose combination of sofosbuvir + velpatasvir (Epclusa) has been evaluated for possible and potential interactions with other drugs.